The role of cyclooxygenase and lipoxygenase in cancer chemoprevention

Drug Metabolism and Drug Interactions

Volumn 17, Issue 1-4, 2000, Pages 109-157

  Cuendet, M ^a   Pezzuto, J M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cancer chemoprevention; Cyclooxygenase; Lipoxygenase

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CURCUMIN; IBUPROFEN; ICOSANOID; INDOMETACIN; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; RESVERATROL; ROFECOXIB; SILYMARIN; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER GROWTH; CANCER PREVENTION; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ENZYME ACTIVITY; HUMAN; LUNG CANCER; METASTASIS; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; TEA; TUMOR CELL;

EID: 0034523901     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2000.17.1-4.109     Document Type: Review

References (274)

1. Prostaglandins and cancer: An update
2. Prostaglandins and cancer. Review
3. Aspirin and the potential role of prostaglandins in colon cancer
4. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs and colon cancer
5. Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyradicals as positive intermediates
6. Effects of eiconanoid synthesis inhibitors on the in vitro growth and prostaglandin E and leukotriene B secretion of a human breast cancer cell line
7. Prostaglandins, their inhibitors and cancer
8. Inhibition of tumor growth by lipoxygenase inhibitors
9. Arachidonate lipoxygenase as essential regulators of cell survival and apoptosis
10. Progress in clinical chemoprevention
11. Recent advances in chemoprevention of cancer
12. Mitogen-inducible prostaglandin G/H synthase: A target for non-steroidal anti-inflammatory drugs
13. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
14. Multiple cyclooxygenases: Cloning of a mitogen-inducible form
15. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissue
16. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence
17. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase)
18. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment
19. Cyclooxygenase isoenzymes: How recent findings affect thinking about nonsteroidal antiinflammatory drugs
20. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
21. Interactions of PGH synthase isoenzymes 1 and 2 with NSAIDs
22. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects
23. Leukotrienes and other products of the 5-lipoxygenase pathway
24. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice
25. Discovery of a second 15S-lipoxygenase in humans
26. Cancer Statistics, 1998
27. Colorectal cancer: Treatment of advanced disease
28. The adenoma-adenocarcinoma sequence in the large bowel: Variations on a theme
29. Prototypic applications of intermediate endpoints in chemoprevention
30. Strategies for identification and clinical evaluation of promising chemopreventive agents
31. Risk and surveillance of individuals with colorectal polyps
32. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention testing program
33. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
34. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer
35. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
36. Cyclooxygenase-1 and -2 deficiency decrease spontaneous intestinal adenomas in the Min mouse
37. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
38. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
39. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
40. Prostaglandin H synthase and xenobiotic oxidation
41. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2
42. Alterations in cellular adhesion and apoptosis in epithelial cells overexpression prostaglandin endoperoxide synthase-2
43. 2 in human colon cancer cells
44. Inflammation and cancer: Role of phagocyte-generated oxidants in carcinogenesis
45. 2-mediated suppression of cellular immunity in colon cancer patients
46. 2 inhibits TNF-alpha release via a mechanism involving IL-10
47. Inhibition of lung tumorigenesis by sulindac: Comparison of two experimental protocols
48. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
49. Apoptosis and APC in colorectal tumorigenesis
50. Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation
51. Expression of 15-lipoxygenase-1 in human colorectal cancer
52. Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells
53. Expression of 5-lipoxygenase by human colorectal carcinoma Caco-2 cells during butyrate-induced cell differentiation
54. Treatment of pancreatic cancer: Current limitations, future possibilities
55. Cancer statistics, 1990
56. Management of pancreatic carcinoma
57. Pancreatic carcinoma
58. Frequent somatic mutations and homozygotous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
59. Pancreatic adenocarcinomas frequently show p53 mutations
60. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma
61. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
62. Insulin-like growth factor I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles
63. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas
64. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
65. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
66. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
67. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas
68. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation
69. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
70. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
71. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes
72. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells
73. Five-lipoxygenase inhibitors reduce PANC-1 survival: The mode of cell death and synergism of MK8686 with gamma linolenic acid
74. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells
75. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells
76. Screening for and evaluation of suspicious breast lesions
77. In vivo effects of indomethacin on the growth of murine mammary tumors
78. A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen in 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acids
79. Prostaglandins and cancer: A review of tumor initiation through tumor metastasis
80. Prostaglandins and breast cancer
81. Nonsteroidal anti-inflammatory drugs and breast cancer
82. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
83. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
84. Cyclooxygenase-2 gene expression in human breast cancer
85. 2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene
86. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens
87. Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor
88. Role of lipoxygenases in breast cancer
89. Characterization of a 15-lipoxygenase in human breast carcinoma BT-20 cells: Stimulation of 13-HODE formation by TGFα/EGF
90. Prostate cancer
91. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
92. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
93. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosome 10p, 10q and 16q in human prostate cancer
94. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma
95. Arachidonic acid stimulates prostate cancer cell growth: Critical role of 5-lipoxygenase
96. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells
97. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer
98. 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma
99. Cancer Statistics, 1999
100. The pathology of lung cancer-changing concepts and newer diagnostic techniques
101. Staging and prognostic factors: Non-small cell lung cancer
102. Aspirin use and lung, colon and breast cancer incidence in a prospective study
103. Expression of cyclooxygenase-2 in human lung carcinoma
104. Increased expression of cyclooxygenase-2 protein in rat lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine
105. High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors
106. Tobacco-specific nitrosamine, an important group of carcinogens in tobacco and tobacco smoke
107. Smoking and lung cancer: Scientific challenges and opportunities
108. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398
109. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice
110. Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice
111. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling
112. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth
113. Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines
114. Inhibitors of lipoxygenase: A new class of cancer chemopreventive agents
115. The mammalian ultraviolet response is triggered by activation of src tyrosine kinases
116. Ultraviolet radiation-induced malignant melanoma in Monodelophis domestica
117. Basic radiobiology
118. An overview of skin cancers
119. Mechanisms of UV-induced inflammation
120. Enhanced keratinocyte prostaglandin synthesis after UV injury is due to increased phospholipase activity
121. Arachidonic acid metabolites in cutaneous carcinomas
122. Inflammation and oxidative stress in carcinogenesis
123. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
124. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin
125. Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2
126. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes
127. Events associated with mouse skin tumor promotion with respect to arachidonic acid metabolism: A comparison between SENCAR and NMRI mice
128. Eicosanoids and multistage carcinogenesis in NMRI mouse skin: Role of prostaglandin E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion)
129. 12-Lipoxygenase isoenzymes in mouse skin tumor development
130. Constitutive expression of 8-lipoxygenase in papillomas and clastogenic effect of lipoxygenase-derived arachidonic acid metabolites in keratinocytes
131. Cytogenetic effects caused by phorbol ester tumor promoters in primary mouse keratinocyte cultures: Correlation with convertogenic activity of TPA in multistage carcinogenesis
132. Cyclooxygenase and lipoxygenase inhibitors in cancer therapy
133. Sunlight and the onset of skin cancer
134. Cancer statistics, 1997
135. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder
136. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors
137. Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam
138. Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine
139. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder
140. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine
141. Hepatocellular carcinoma
142. Hepatocellular carcinoma: Recent progress
143. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation
144. The morphologic transition in hepatocellular carcinoma. A comparison of the individual histologic features disclosed by ultrasound-guided free-needle biopsy with those of autopsy
145. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression
146. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma
147. Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats
148. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma
149. Aspirin induced apoptosis in gastric cancer cells
150. Cyclooxygenase-2 expression in human esophageal carcinoma
151. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion
152. COX-2 expression in retinoblastoma
153. NSAIDs and colorectal cancer: Evolving concepts of their chemopreventive actions
154. Prostaglandins in human colonic carcinoma
155. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors
156. Effects of piroxicam in primary intestinal tumors induced in rats by N-methylnitrosourea
157. Sulindac for polyposis of the colon
158. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis (FAP)
159. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study
160. A hypothesis: Nonsteroidal antiinflammatory drugs reduce the incidence of large-bowel cancer
161. Aspirin use and risk of fatal cancer
162. Nonsteroidal antiinflammatory drugs and colorectal cancer
163. Reduced risk of large-bowel adenomas among aspirin users
164. Cyclooxygenase-2 inhibitors in tumorigenesis (part I)
165. Prostaglandins and cancer
166. Towards a better aspirin
167. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
168. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
169. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen
170. Comparison of the effect of refecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebocontrolled trial
171. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines
172. A selective cyclooxygenase-2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells
173. Inhibition of lung tumorigenesis by NSAIDs: A working hypothesis
174. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
175. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
176. R-Flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: Implications for prophylaxis and treatment of colon cancer
177. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
178. Arthritis drug approved for polyp prevention blazes trail for other prevention trials
179. Inhibitory effects of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin
180. Curcumin
181. Studies on the inhibitory effects of curcumin and eugenol on the formation of reactive oxygen species and the oxidation of ferrous iron
182. Pharmacology of curcumin
183. Turmeric and curcumin as topical agents in cancer therapy
184. Pharmacology of diferuloylmethane (curcumin), a non-steroidal antiinflammatory agent
185. Evaluation of antiinflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation
186. Antioxidant activity of curcumin and related compounds
187. Natural antioxidant III. Antioxidative components isolated from rhizome of Curcuma longa L
188. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate
189. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis
190. Inhibitory effect of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene
191. Chemopreventive effect of tumeric against stomach and skin tumors induced by chemical carcinogenesis in Swiss mice
192. Inhibitory effect of dietary curcumin on gastrointestinal tumorigenesis in mice
193. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon
194. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound
195. Some perspectives on dietary inhibition of carcinogenesis: Studies with curcumin and tea
196. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion
197. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells
198. Progress in cancer chemoprevention
199. Tea
200. Tea and cancer: A review
201. A Polish case-control study
202. Cancer mortality in relation to national consumption of cigarettes, solid fuel, tea and coffee
203. Tea consumption and cancer incidence in a prospective cohort study of post-menopausal women
204. Cigarette smoking, alcohol, tea and coffee consumption and pancreas cancer risk: A case-control study from Opole, Poland
205. Tea in chemoprevention of cancer: Epidemiologic and experimental studies
206. Tea and tea polyphenols in cancer prevention
207. Tea and tea polyphenols inhibit cell hyperproliferation, lung tumorigenesis, and tumor progression
208. Antitumor promoting activity of (-)-epigallocatechin gallate, the main constituent of "tannin" in green tea
209. Protection against polycyclic aromatic hydrocarbon-induced skin tumor initiation in mice by green tea polyphenols
210. Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea
211. Inhibitory effect of topical application of a green tea polyphenol fraction on tumor initiation and promotion in mouse skin
212. Inhibition of 12-O-tetradecanoyl-phorbol-13-acetate-caused tumor promotion in 7,12-dimethylbenz(a)anthracene-initiated SENCAR mouse skin by a polyphenolic fraction isolated from green tea
213. Protection against malignant conversion of chemically induced benign skin papillomas to squamous cell carcinomas in SENCAR mice by a polyphenolic fraction isolated from green tea
214. Inhibitory effects of black tea, green tea, decaffeinated black tea, and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7,12-dimethylbenz[a]anthracene-initiated SKH-1 mice
215. Inhibition of 12-O-tetradecanoylphorbol-13-acetate and other skin tumor-promoter-caused induction of epidermal interleukin-1 alpha mRNA and protein expression in SENCAR mice by green tea polyphenols
216. Protection against ultraviolet B radiation-induced effects in the skin of SKH-1 hairless mice by a polyphenolic fraction isolated from green tea
217. Structure-antioxidant activity relationships of flavonoids and phenolic acids
218. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants
219. Inhibition of peroxynitrite-mediated tyrosine nitration by catechin polyphenol
220. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: Possible role in cancer chemoprevention
221. Activation of mitogen-activated protein kinases by green tea polyphenols: Potential signaling pathways in the regulation of antioxidant-responsive element-mediated phase II enzyme gene expression
222. Inhibition of carcinogenesis by tea: Bioavailability of tea polyphenols and mechanisms of actions
223. Polyphenols as inhibitors of carcinogenesis
224. Modulatin of the UVA activation of haem oxygenase, collagenase and cyclooxygenase gene expression by epigallocatechin in human skin cells
225. The protective effect of indomethacin on photocarcinogenesis in hairless mice
226. The chemistry of silymarin (silybin), the active principle of the fruits of Silybum marianum (L) Gaertn (Carduus marianus) (L)
227. Chemistry and analysis of silymarin from Silybum marianum Gaertn
228. A review of plants used in the treatment of liver disease: Part I
229. Protection against microcystin-LR-induced hepatotoxicity by silymarin: Biochemistry, histopathology, and lethality
230. Studies on the antioxidant and free radical scavenging properties of IdB 1016 a new flavanolignan complex
231. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016
232. Inhibition of transformation in cultured rat tracheal epithelial cells by potential chemopreventive agents
233. Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation-promotion protocol
234. Inhibitory effect of silymarin, an antihepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice
235. Protective effects of silymarin against photocarcinogenesis in mouse skin model
236. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: Inhibition of mRNA expression of an endogenous tumor promoter TNFα
237. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in SENCAR mouse skin tumorigenesis model
238. Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol-13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1α expression in SENCAR mouse epidermis: Implications in the prevention of stage I tumor promotion
239. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression
240. Antiplatelet activity of cis-resveratrol
241. Effects of stilbenes on arachidonate metabolism in leukocytes
242. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function
243. Cancer chemoprevention activity of resveratrol, a natural product derived from grapes
244. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells
245. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity
246. Inhibitory effects of phytopolyphenols on TPA-induced transformation, PKC activation, and c-jun expression in mouse fibroblast cells
247. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in fibroblast cells
248. v-src induces prostaglandin synthase 2 gene expression by activation of the c-N-terminal kinase and the c-Jun transcription factor
249. The cyclic AMP response element plays an essential role in the expression of human prostaglandin-endoperoxide synthase 2 gene in differentiated U937 monocytic cells
250. Antitumor promotion by phenolic antioxidants: Inhibition of AP-1 activity through induction of Fra expression
251. Difference in transcriptional regulatory function between c-Fos and Fra-2
252. The regulation of AP-1 activity by mitogen-activated protein kinases
253. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase
254. The antibacterial action of honey: An in vitro study
255. Caffeic acid is a selective inhibitor for leukotriene biosynthesis
256. Antitumor properties of honey
257. The analysis of bud exudate of Populus x euramericana and of propolis by gas chromatography-mass spectrometry
258. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon
259. Inhibition of tumor promoter-mediated processes in mouse skin and bovine lens by caffeic acid phenethyl ester
260. Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells
261. Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation
262. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure
263. Western diet and Western diseases: Some hormonal and biochemical mechanisms and associations
264. Soybeans inhibit mammary tumors in models of breast cancer
265. Genistein suppresses mammary cancer in rats
266. Cancer chemoprevention agents discovered by activity-guided fractionation: A review
267. Bioaassay methods useful for activity-guided isolation of natural product cancer chemoprevention agents
268. Enhanced endothelial cell retraction mediated by 12(S)-HETE: A proposed mechanism for the role of platelets in tumor cell metastasis
269. The consequences of the chemotherapy of Hodgkin's disease: The 10th Annual David A. Karnofsky Lecture
270. Effects of dietary menhaden oil, soy and a cyclooxygenase inhibitor on human breast cancer cell growth and metastasis in nude mice
271. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
272. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease
273. Prevention of cancer in the next millenium: Report of the Chemoprevention Working Group to the American Association for Cancer Research